Article http://dx.doi.org/10.26855/ijcemr.2023.10.028

Analysis of Death and Related Factors Within 1 Year in Elderly Patients on Maintenance Hemodialysis


Xingfeng Zhuo*, Yan Xu, Xu Huang, Jie Sun, Yao Yao

Outpatient Department, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.

*Corresponding author: Xingfeng Zhuo

Published: November 30,2023


Objective: To investigate the short-term (within 3 to 12 months) survival of elderly MHD patients and analyze the mortality risk factors of patients. Methods: The clinical data of 45 elderly patients with regular MHD treatment from January 2015 to December 2022 and died within 3 to 12 months were selected as the death group. Moreover, 45 elderly patients with regular MHD treatment and the survival period was more than 12 months were selected as the control group. The cause of death, basic clinical data, and la-boratory indicators were investigated. Results: The mean time from hemodialysis initiation to death for the 45 patients in the death group was (9.04 ± 2.16) months. The primary cases of diabetic nephropathy (42.22%) and hypertensive renal damage (28.89%), the causes of death: cardiovascular disease (46.67%) ranked first, and the causes of infection (22.22%) ranked second. Logistic Regression analysis, the results showed that advanced age, use of central venous catheter, low BMI, low PA, and combined diabetes were risk factors for short-term death in MHD patients (P <0.05). Conclusion: The primary disease of elderly MHD patients dying in the short term is mainly diabetic nephropathy, and the cause of death is the cause of cardiovascular disease. Early effective control of blood glucose and blood pressure, improved nutritional status, reasonable selection of vascular access, active pre-vention and treatment of cardiovascular disease and infection complications, which is helpful to prolong the survival time of elderly MHD patients.


[1] Kumagai E, Hosohata K, Furumachi K, et al. Range of serum transthyretin levels in hemodialysis patients at a high risk of 1-year mortality: A retrospective cohort study [J]. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2021. DOI: 10.1111/1744-9987.13768.

[2] Park J J. Why Does the Intravenous Iron Supplementation Not Work in Heart Failure Patients on Hemodialysis? [J]. CardioMetabolic SyndromJournal, 2022. DOI:10.51789/cmsj.2022.2.e18.

[3] Wang Yiping, Qin Lianxiang, Yang Nining, et al.  Short-term death factors analysis in elderly maintenance hemodialysis patients [J]. Military Medicine, 2016, 40 (8): 672-675.

[4] Du L, Huo L, Hou J, et al. Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study [J]. Biopharmaceutics & drug disposition. 2023. 

[5] Ilda M B, Veli Süha ztürk, Recep zgür, et al. Primary Patency Rates of Endovascular Interventions in Hemodialysis Patients with Central Venous Stenosis and Occlusions [J]. Acta Angiologica, 2021, 1(1):17-21. DOI:10.5603/AA.2021.0003.

[6] Soleymanian T, Kokabeh Z, Ramaghi R, et al. Clinical outcomes and quality of life in hemodialysis diabetic patients versus non-diabetics [J]. J Nephropathol, 2017, 6(2): 81-89.

[7] Lv Y, Tian Y F, Zhao Y R, et al. Efficacy of Roxadustat in the Treatment of Hemodialysis in Patients with Renal Anemia [J]. Journal of Biological Regulators and Homeostatic Agents, 2022, 36(6): 1921-1927. DOI: 10.23812/j.biol.regul.homeost.agents.20223606.200.

[8] Sun Linlin, Li Lin, Susensen. The diagnosis and prognostic value of cardiovascular complications in ESRD patients [J]. Chinese Experimental Diagnostics, 2018, 22 (6): 1106-1109.

[9] Vigan J, Ahoui S, Hounsou D, et al. Left ventricular hypertrophy in chronic hemodialysis patients at CNHU-HKM of Cotonou [J]. Nephrol Ther, 2018, 14(1): 29-34.

[10] Nazariomarouco C, Caeiro F, Costa B M D, et al. The use of hemodialysis in hypercalcemic crisis secondary to primary hyperparathyroidism [J]. Portuguese Journal of Nephrology & Hypertension, 2021. DOI:10.32932/pjnh.2021.07.134.

[11] Fox C S, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis [J]. Lancet, 2012, 380(9854): 1662-1673.

[12] Tang Ying, Zhong Yihong, Gong Shaomin, et al.  Hemodialysis patients with end-stage renal disease infection death investigation [J]. Chinese Journal of Kidney Disease, 2011, 27 (6): 406-410.

[13] Abascal R E C, José Ignacio Ramírez Gómez, Carlos Gutiérrez Gutiérrez, et al. Angioaccess for hemodialysis in kidney transplantation [J]. 2021. DOI:10.32457/ijmss.v8i1.638.

How to cite this paper

Analysis of Death and Related Factors Within 1 Year in Elderly Patients on Maintenance Hemodialysis

How to cite this paper: Xingfeng Zhuo, Yan Xu, Xu Huang, Jie Sun, Yao Yao. (2023) Analysis of Death and Related Factors Within 1 Year in Elderly Patients on Maintenance HemodialysisInternational Journal of Clinical and Experimental Medicine Research7(4), 673-676.

DOI: http://dx.doi.org/10.26855/ijcemr.2023.10.028